06855.HK
Ascentage Pharma Group International Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 27.20
−3.61%Oct 21, 2026, 01:39 UTC
China’s Center for Drug Evaluation included ASCENTAGE PHARMA GROUP INTERNATIONAL’s lisaftoclax (APG-2575) in its breakthrough therapy designation list for use with acalabrutinib to treat adults with previously untreated CLL/SLL.
Source:Oct 20, 2026, 23:30 UTC
China's National Shanghai Center For New Drug Safety Evaluation & granted Ascentage Pharma's lisaftoclax Breakthrough Therapy Designation in combination with acalabrutinib for treatment-naïve adults with CLL/SLL.
Source:Sep 28, 2026, 16:33 UTC
Yang Dajun, executive director and board chairman of Ascentage Pharma (06855), bought a total of 38,630 shares on-market on September 23, 24 and 25 at an average price of HK$29.95 per share for about HK$1.1571 million, equal to roughly 0.01% of total issued share capital.
Source:Aug 19, 2026, 23:00 UTC
Ascentage Pharma appointed Dr. Faical Miyara as Chief Business Officer.
Source:Aug 19, 2026, 23:00 UTC
Ascentage Pharma reported interim unaudited financial results for the first half of 2026, with revenue increasing 29% year-over-year to US$44.5 million (RMB302.2 million), primarily due to increased product sales.
Aug 2, 2026, 23:46 UTC
Ascentage Pharma appointed Faiçal Miyara as Chief Business Development Officer and Jim Ziegler as Chief Commercial Operations Officer, both reporting to Chairman and CEO Yang Dajun.
Jul 19, 2026, 13:12 UTC
Ascentage Pharma Group files a shelf registration statement with the U.S. SEC for an at-the-market offering of up to $200 million in American Depositary Shares.
May 31, 2026, 23:30 UTC
Ascentage Pharma presented its first dataset on MDM2-p53 inhibitor alrizomadlin (APG-115) in pediatric solid tumors at the ASCO 2026 Annual Meeting.